Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients | Zendy

Pia Burman | Zendy; Britt Edén Engström | Zendy; Bertil Ekman | Zendy; F. Anders Karlsson | Zendy; Erik Schwarcz | Zendy; Jeanette Wahlberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients

Author(s) -

Pia Burman,

Britt Edén Engström,

Bertil Ekman,

F. Anders Karlsson,

Erik Schwarcz,

Jeanette Wahlberg

Publication year - 2015

Publication title -

european journal of endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 148

eISSN - 1479-683X

pISSN - 0804-4643

DOI - 10.1530/eje-15-0807

Subject(s) - cabergoline , medicine , endocrinology , morning , prolactin , cushing's disease , prospective cohort study , cortisol awakening response , hydrocortisone , disease , hormone

The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research